Synlogic reports Q4 2022 net loss $16.7M; PKU Phase 3 on track for H1 2023

SYNLOGIC, INC.

Q4 2022 net loss $16.7M ($0.24/share) vs $15.1M ($0.21) in Q4 2021; full year net loss $66.1M ($0.92/share).
Cash, cash equivalents and marketable securities $77.6M; projected runway into H2 2024.
PKU program SYNB1934 on track for Phase 3 trial initiation in H1 2023; Rare Pediatric Disease Designation granted.
SYNB1353 for HCU received Rare Pediatric Disease Designation; proof of mechanism in Phase 1 study.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

SYNLOGIC, INC. reported financial results for the quarter and full year ended December 31, 2022.

Period: the quarter and full year ended December 31, 2022
Result: reported results

Exact text from the filing

On March 29, 2023, Synlogic, Inc. (the “Company”) announced its financial results for the quarter and full year ended December 31, 2022.

View on SEC.gov

8 earnings releases filed in the last 30 days. Browse all earnings releases →

SYNLOGIC, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-010430

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.